PE20220141A1 - Inhibidores de la proteina tirosina fosfatasa - Google Patents
Inhibidores de la proteina tirosina fosfatasaInfo
- Publication number
- PE20220141A1 PE20220141A1 PE2021001646A PE2021001646A PE20220141A1 PE 20220141 A1 PE20220141 A1 PE 20220141A1 PE 2021001646 A PE2021001646 A PE 2021001646A PE 2021001646 A PE2021001646 A PE 2021001646A PE 20220141 A1 PE20220141 A1 PE 20220141A1
- Authority
- PE
- Peru
- Prior art keywords
- bicyclic
- membered
- heteroaryl
- heterocycle
- cyano
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a compuestos de Formula I o una sal farmaceuticamente aceptable del mismo, donde: L1 se selecciona de un enlace directo, S, CH2, O, NH y Se; R1 se selecciona de hidrogeno y metilo; R2 se selecciona de fenilo, un heteroarilo de 5 a 6 miembros en donde el heteroarilo contiene 1 a 4 heteroatomos seleccionados del grupo que consiste en N, O y S, en donde un heteroatomo de N se puede sustituir con O para formar un oxido, un cicloalquilo biciclico de 8-10 miembros, un arilo biciclico de 10 miembros, un heterociclo biciclico de 9-10 miembros, en donde el heterociclo contiene 1 a 3 heteroatomos seleccionados del grupo que consiste en N, O y S, y un heteroarilo biciclico de 9-10 miembros, en donde el heteroarilo biciclico contiene 1 a 3 heteroatomos seleccionados del grupo que consiste en N, O y S, en donde el fenilo, heteroarilo, cicloalquilo biciclico, arilo biciclico, heterociclo biciclico y heteroarilo biciclico se sustituyen opcionalmente con halogeno, ciano, oxo, C1-C3 alquilo opcionalmente sustituido con 1 a 3 grupos seleccionados de halogeno, ciano y OH, C3-C6 cicloalquilo, C1-C3 alcoxi opcionalmente sustituido con 1 a 3 grupos seleccionados de halogeno, ciano y OH, NHRa, y un heterociclo de 3 a 6 miembros opcionalmente sustituido con 1 a 3 grupos seleccionados de halogeno, ciano y OH, en donde el heterociclo contiene 1 o 2 heteroatomos seleccionados de N, O y S. R2 se puede seleccionar del grupo de fenilo, 2-clorofenilo, 3-clorofenilo, 2,3-diclorofenilo, 2-amino-3-cloropiridin-4-ilo, 2,3-dicloropiridin-4-ilo, entre otros. Tambien se refiere a composiciones farmaceuticas. Dichos compuestos son utiles en el tratamiento de enfermedades hiperproliferativas y neoplasicas al inhibir la proteina SHP2 necesaria para la activacion completa de la via de Ras/ERK1/2, una cascada de senalizacion clave en la biologia del cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828356P | 2019-04-02 | 2019-04-02 | |
| US202062992558P | 2020-03-20 | 2020-03-20 | |
| PCT/IB2020/053019 WO2020201991A1 (en) | 2019-04-02 | 2020-03-30 | Protein tyrosine phosphatase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220141A1 true PE20220141A1 (es) | 2022-01-27 |
Family
ID=70277430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001646A PE20220141A1 (es) | 2019-04-02 | 2020-03-30 | Inhibidores de la proteina tirosina fosfatasa |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11634417B2 (es) |
| EP (1) | EP3947367A1 (es) |
| JP (2) | JP7284830B2 (es) |
| KR (1) | KR102698608B1 (es) |
| CN (1) | CN113874363B (es) |
| AU (1) | AU2020251841B2 (es) |
| BR (1) | BR112021018664A2 (es) |
| CA (1) | CA3135555C (es) |
| CL (2) | CL2021002542A1 (es) |
| CO (1) | CO2021013030A2 (es) |
| CR (1) | CR20210501A (es) |
| CU (1) | CU20210080A7 (es) |
| DO (1) | DOP2021000206A (es) |
| EC (1) | ECSP21072994A (es) |
| GE (2) | GEP20237561B (es) |
| IL (2) | IL320682A (es) |
| MA (1) | MA55511A (es) |
| MX (1) | MX2021012122A (es) |
| PE (1) | PE20220141A1 (es) |
| PH (1) | PH12021552227A1 (es) |
| PY (1) | PY2018672A (es) |
| SG (1) | SG11202110502PA (es) |
| TW (1) | TWI766261B (es) |
| UY (1) | UY38628A (es) |
| WO (1) | WO2020201991A1 (es) |
| ZA (1) | ZA202108443B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
| MA53921A (fr) | 2018-10-17 | 2022-01-26 | Array Biopharma Inc | Inhibiteurs de protéine tyrosine phosphatase |
| BR112021018664A2 (pt) * | 2019-04-02 | 2021-11-23 | Array Biopharma Inc | Inibidores de proteína tirosina fosfatase |
| CA3183032A1 (en) | 2020-06-18 | 2021-12-23 | Mallika Singh | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| CR20230165A (es) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer |
| KR20230147159A (ko) * | 2021-03-23 | 2023-10-20 | 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 | 헤테로고리로 치환된 메탄온계 유도체, 이의 조성물 및 의약적 용도 |
| CN117083285A (zh) * | 2021-03-31 | 2023-11-17 | 南京明德新药研发有限公司 | 一系列含Se的吡嗪类化合物及其应用 |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| KR20230165309A (ko) * | 2021-04-01 | 2023-12-05 | 어레이 바이오파마 인크. | Shp2 억제제의 결정질 형태 |
| CN117460725A (zh) * | 2021-04-01 | 2024-01-26 | 阵列生物制药公司 | Shp2抑制剂的晶型 |
| IL308193A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| TW202244049A (zh) * | 2021-05-12 | 2022-11-16 | 大陸商藥雅科技（上海）有限公司 | Shp2磷酸酶抑制劑的製備及其應用 |
| CN115960109B (zh) * | 2021-05-31 | 2024-06-25 | 药雅科技(上海)有限公司 | 稠环类shp2磷酸酶抑制剂的制备及其应用 |
| IL309984A (en) | 2021-07-09 | 2024-03-01 | Kanaph Therapeutics Inc | Shp2 inhibitor and use thereof |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023061263A1 (zh) * | 2021-10-14 | 2023-04-20 | 北京泰德制药股份有限公司 | Shp2抑制剂、包含其的药物组合物及其用途 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| CA3256136A1 (en) * | 2022-03-23 | 2023-09-28 | Array Biopharma Inc. | CRYSTALLINE SALT FORM OF AN SHP2 INHIBITOR |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN115177622B (zh) * | 2022-07-19 | 2024-09-17 | 中南大学湘雅二医院 | 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| PE20260039A1 (es) | 2023-04-07 | 2026-01-09 | Revolution Medicines Inc | Inhibidores macrociclicos de ras |
| TW202448897A (zh) | 2023-04-14 | 2024-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| WO2024218632A1 (en) | 2023-04-17 | 2024-10-24 | Array Biopharma Inc. | Erk protein kinase inhibitors |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US7834178B2 (en) | 2006-03-01 | 2010-11-16 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
| RU2629116C2 (ru) | 2011-10-14 | 2017-08-24 | Эррэй Биофарма Инк. | Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их |
| JP6378182B2 (ja) | 2012-08-27 | 2018-08-22 | アレイ バイオファーマ、インコーポレイテッド | 過剰増殖性│疾患の処置のためのセリン／スレオニンキナーゼ阻害剤 |
| RU2643361C2 (ru) | 2013-09-30 | 2018-02-01 | Кореа Рисёч Инститьют Оф Кемикал Текнолоджи | Новые производные триазолопиразина и их применение |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| US10093646B2 (en) | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
| ES2699354T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2 |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| ES2805232T3 (es) * | 2015-06-19 | 2021-02-11 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| ES2824576T3 (es) | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| AU2017274199B2 (en) | 2016-05-31 | 2021-09-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| EA202092442A3 (ru) | 2016-06-07 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| CN109415360B (zh) | 2016-06-14 | 2021-11-02 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| KR102598895B1 (ko) * | 2016-07-12 | 2023-11-07 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
| US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| AU2018239542C1 (en) * | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
| WO2018218133A1 (en) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| WO2019051084A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER |
| TW202517628A (zh) | 2017-09-11 | 2025-05-01 | 美商克魯松藥物公司 | Shp2之八氫環戊烷并[c]吡咯別構抑制劑 |
| US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| TW201927791A (zh) | 2017-12-15 | 2019-07-16 | 美商銳新醫藥公司 | 作為變構shp2抑制劑的多環化合物 |
| WO2019152454A1 (en) | 2018-01-30 | 2019-08-08 | Research Development Foundation | Shp2 inhibitors and methods of use thereof |
| WO2019183364A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| BR112020019385A2 (pt) | 2018-03-21 | 2021-03-30 | Relay Therapeutics, Inc. | Inibidores de shp2 fosfatase e métodos de uso dos mesmos |
| CN112368272B (zh) | 2018-03-21 | 2023-04-21 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
| SG11202100199UA (en) | 2018-08-10 | 2021-02-25 | Navire Pharma Inc | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
| US20210393623A1 (en) * | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| MA53921A (fr) | 2018-10-17 | 2022-01-26 | Array Biopharma Inc | Inhibiteurs de protéine tyrosine phosphatase |
| BR112021018664A2 (pt) * | 2019-04-02 | 2021-11-23 | Array Biopharma Inc | Inibidores de proteína tirosina fosfatase |
-
2020
- 2020-03-30 BR BR112021018664A patent/BR112021018664A2/pt unknown
- 2020-03-30 EP EP20718387.2A patent/EP3947367A1/en active Pending
- 2020-03-30 GE GEAP202015746A patent/GEP20237561B/en unknown
- 2020-03-30 CU CU2021000080A patent/CU20210080A7/es unknown
- 2020-03-30 MA MA055511A patent/MA55511A/fr unknown
- 2020-03-30 PH PH1/2021/552227A patent/PH12021552227A1/en unknown
- 2020-03-30 JP JP2021558566A patent/JP7284830B2/ja active Active
- 2020-03-30 WO PCT/IB2020/053019 patent/WO2020201991A1/en not_active Ceased
- 2020-03-30 MX MX2021012122A patent/MX2021012122A/es unknown
- 2020-03-30 IL IL320682A patent/IL320682A/en unknown
- 2020-03-30 GE GEAP202315746A patent/GEAP202315746A/en unknown
- 2020-03-30 CR CR20210501A patent/CR20210501A/es unknown
- 2020-03-30 AU AU2020251841A patent/AU2020251841B2/en active Active
- 2020-03-30 SG SG11202110502PA patent/SG11202110502PA/en unknown
- 2020-03-30 PE PE2021001646A patent/PE20220141A1/es unknown
- 2020-03-30 CA CA3135555A patent/CA3135555C/en active Active
- 2020-03-30 CN CN202080036271.6A patent/CN113874363B/zh active Active
- 2020-03-30 KR KR1020217035641A patent/KR102698608B1/ko active Active
- 2020-03-31 US US16/835,702 patent/US11634417B2/en active Active
- 2020-04-01 TW TW109111284A patent/TWI766261B/zh active
- 2020-04-01 UY UY0001038628A patent/UY38628A/es not_active Application Discontinuation
- 2020-05-06 PY PY202002018672A patent/PY2018672A/es unknown
-
2021
- 2021-09-19 IL IL286462A patent/IL286462A/en unknown
- 2021-09-29 CO CONC2021/0013030A patent/CO2021013030A2/es unknown
- 2021-09-30 EC ECSENADI202172994A patent/ECSP21072994A/es unknown
- 2021-09-30 DO DO2021000206A patent/DOP2021000206A/es unknown
- 2021-09-30 CL CL2021002542A patent/CL2021002542A1/es unknown
- 2021-10-29 ZA ZA2021/08443A patent/ZA202108443B/en unknown
-
2022
- 2022-04-13 US US17/720,070 patent/US11884664B2/en active Active
-
2023
- 2023-03-27 JP JP2023049681A patent/JP2023078421A/ja active Pending
- 2023-11-17 US US18/512,473 patent/US20240124453A1/en not_active Abandoned
-
2024
- 2024-01-19 CL CL2024000183A patent/CL2024000183A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220141A1 (es) | Inhibidores de la proteina tirosina fosfatasa | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20241063A1 (es) | Composiciones y metodos para la inhibicion de ras | |
| PE20220592A1 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos | |
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| MX2024001824A (es) | Compuestos heterociclicos y metodos de uso. | |
| PE20191755A1 (es) | Derivados de pirazol como inhibidores de malt 1 | |
| CR20220312A (es) | Compuestos tricíclicos sustituidos | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| PE20240879A1 (es) | Inhibidor sos1 y uso del mismo | |
| CR20210441A (es) | Inhibidores de la pcsk9 y métodos de uso de los mismos | |
| PE20210004A1 (es) | Inhibidores de mcl-1 | |
| ATE499097T1 (de) | Monozyklische heterozyklen als kinase-hemmer | |
| PE20090435A1 (es) | Inhibidores de tetrahidropiranocromeno de gamma secretasa | |
| PE20231986A1 (es) | Compuesto de heteroarilcarboxamida | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| EA202091475A1 (ru) | ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА | |
| CY1120325T1 (el) | Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης | |
| EA201070442A1 (ru) | НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ | |
| MX2024002391A (es) | Inhibidores de indolina de kif18a. | |
| PE20211770A1 (es) | 3,3-difluoroalilaminas o sales de las mismas y composiciones farmaceuticas que las comprenden | |
| PE20200445A1 (es) | Inhibidores pirazolicos de magl | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| PE20241934A1 (es) | Inhibidores de raf quinasa y metodos de uso de los mismos |